CollPlant Biotechnologies (CLGN) Return on Sales (2017 - 2026)

CollPlant Biotechnologies' Return on Sales history runs 10 years deep, the most recent figure standing at 0.43% for Q1 2026.

• Quarterly Return on Sales fell 42.0% year-over-year to 0.43% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.91% (down 80.0% YoY) and the FY2025 annual result came in at 0.17%, up 59.0% from the prior year.
• Return on Sales was 0.43% for Q1 2026 at CollPlant Biotechnologies, up from 5.33% in the prior quarter.
• Across five years, Return on Sales topped out at 0.44% in Q1 2024 and bottomed at 11.36% in Q3 2024.
• A 5-year average of 1.55% and a median of 0.42% in 2022 frame the typical range for Return on Sales.
• Annual changes were most pronounced in 2024 — Return on Sales sank 1135 bps — and 2025, when it surged 1090 bps.
• CollPlant Biotechnologies' Return on Sales stood at 4.68% in 2022, then soared by 83 bps to 0.81% in 2023, then tumbled by 100 bps to 1.63% in 2024, then tumbled by 227 bps to 5.33% in 2025, then jumped by 92 bps to 0.43% in 2026.
• Business Quant data shows CLGN's Return on Sales at 0.43% in Q1 2026, 5.33% in Q4 2025, and 0.46% in Q3 2025.